Blog Keep up to date with our latest expert insights into the world of genomic healthcare. FEATURED Let’s Go Dotty for Lynch Syndrome – bridging the gap between testing and diagnosis FEATURED The NEW clinically validated NGS and bioinformatics solution for hereditary cancer testing: GALEAS Hereditary Plus – All you need to know Load More SEARCHSubmitCategoriesAll CategoriesCell3 DirectCell3 targetCustomGermlineInfectious diseaseOncologyPre-analyticalUncategorized Let’s Go Dotty for Lynch Syndrome – bridging the gap between testing and diagnosis March 22, 2024 The NEW clinically validated NGS and bioinformatics solution for hereditary cancer testing: GALEAS Hereditary Plus – All you need to know February 28, 2024 Screening for rare disease with next generation sequencing February 24, 2024 4 key factors influencing NGS custom panel design December 08, 2023 FFPE, cfDNA and gDNA: The guide to DNA sample types used in next generation sequencing December 07, 2023 Hereditary cancer testing: Challenges and opportunities for genomic centres December 01, 2023 How our custom NGS panels are being used for clinical utility November 29, 2023 The power of SPRI technology: Tips for DNA size selection and effective clean-up in NGS workflows November 01, 2023 The NEW sample-to-report NGS bladder cancer test: GALEAS Bladder – All you need to know September 20, 2023 To consolidate multiple testing strategies for haematological malignancies, our customer designed the first Nonacus NGS panel for both myeloid and lymphoid neoplasia August 02, 2023 Pages: 123Load more Blog Posts Sign up to receive updates
